FORA Capital’s Nuvation Bio NUVB Stock Holding History

FORA Capital’s Portfolio NUVB Stock Details NUVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-17,136	Closed	-$154K	–	551
2025 Q4	$154K	Buy	+17,136	New	+$106K	0.02%	400

Other funds holding NUVB

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

DFO

Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

FORA Capital's NUVB Position: Q1 2026 in Review

FORA Capital sold out of Nuvation Bio (NUVB) in Q1 2026, closing a stake of 17,136 shares — an estimated $154K sold.

FORA Capital first reported a position in NUVB in Q4 2025 and held it in 1 quarter. The position peaked at $154K in Q4 2025. 231 funds tracked by Wall St. Rank hold NUVB as of Q1 2026.

FORA Capital reported no remaining Nuvation Bio position as of Q1 2026 after selling out during the quarter.
FORA Capital sold 17,136 Nuvation Bio shares in Q1 2026, an estimated $154K.
FORA Capital first reported a position in Nuvation Bio in Q4 2025 and held it in 1 quarter.
FORA Capital's Nuvation Bio position peaked at $154K in Q4 2025.
231 funds tracked by Wall St. Rank held Nuvation Bio as of Q1 2026.

Based on FORA Capital's 13F filing for Q1 2026, filed 15 May 2026.